Cystic Fibrosis Liver Disease Clinical Research Workshop
Total Page:16
File Type:pdf, Size:1020Kb
Cystic Fibrosis Liver Disease Clinical Research Workshop JUNE 8 - 9, 2009 LISTER HILL AUDITORIUM NIH CAMPUS, BETHESDA, MD Organizing Committee Michael Narkewicz, M.D. University of Colorado Denver Michael Knowles, M.D. The University of North Carolina at Chapel Hill Patricia Robuck, Ph.D., M.P.H. National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Catherine McKeon, Ph.D. National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Jay H. Hoofnagle, M.D. National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bruce Marshall, M.D. Cystic Fibrosis Foundation Marilyn Siegel, M.D. Washington University Medical Center Edward Doo, M.D. National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health SPONSORS: The National Institute of Diabetes and Digestive and Kidney Diseases, the Office of Rare Diseases, and the Cystic Fibrosis Foundation. The lunch and poster session are sponsored by the Cystic Fibrosis Foundation. Cystic Fibrosis Liver Disease | Clinical Research Workshop iii Table of Contents Organizing Committee iii Agenda ix Speaker Abstracts Cystic Fibrosis Liver Disease: Clinical Features and Definitions Michael R. Narkewicz 3 Prevalence and Epidemiology of Cystic Fibrosis Liver Disease Jean Pappas Molleston 6 Cystic Fibrosis Liver Disease: Clinical Outcomes Peter Durie, Susanne Schibli, Rakesh Battacharjee, Mary Corey 8 Pathogenesis of Cystic Fibrosis Liver Disease Steven D. Freedman 10 The Pathology of Cystic Fibrosis Liver Disease David E. Kleiner 15 Genetic Modifiers of Cystic Fibrosis Liver Disease Michael R. Knowles for Jaclyn Bartlett, Peter Durie, and the Gene Modifier Study Group 17 Protein Folding Defects in Liver Disease: Alpha-1-antitrypsin Deficiency Jeffrey Teckman 19 Cystic Fibrosis Liver Disease: CFTR and the Liver Andrew P. Feranchak 21 The CFTR-/- Pig: Liver and Gallbladder Disease David K. Meyerholz, David A. Stoltz, Michael J. Welsh 24 Medical and Surgical Therapy of CF-associated Liver Disease Saul J. Karpen 25 Liver Transplantation in Children With Cystic Fibrosis: Status and Unanswered Questions George V. Mazariegos 27 Biomarkers as Tools for Early Disease Detection Nicole Mayer Hamblett 29 Cystic Fibrosis Liver Disease | Clinical Research Workshop v Table of Contents Emerging Techniques for Developing Novel Serum Biomarkers Keyur Patel 31 Biomarkers of Cystic Fibrosis Liver Disease Ross W. Shepherd, Grant Ramm, Peter Lewindon 33 Ultrasound and CT Imaging of Liver Fibrosis and Other Disease Marilyn J. Siegel 35 MRI Methods of Assessing Liver Fibrosis and Disease Claude B. Sirlin 37 Elastography to Assess Liver Fibrosis and Cirrhosis Detlef Schuppan 39 Agenda Poster Abstracts Long-term Effect of Simultaneous Liver-Pancreas Transplant on Hepatic, Pulmonary, and Pancreatic Function in Three Cystic Fibrosis Patients Molly Bozic, Jean Molleston, M. Howenstine, J. Fridell 43 Paracrine Induction of Sulfotransferase 1E1 in HepG2 Hepatocytes During Co-culture With CFTR-deficient MMNK-1 Cholangiocytes Charles N. Falany, Dongning He, Li Li, Teresa W. Wilborn, Melissa Runge-Morris 45 Quantitative Imaging of Biliary Fibrosis Progression Using a Small Molecule αv β6 Integrin Ligand With Nanomolar Affinity Yury Popov, Preeti Misra, Kumar Ranjan Bhushan, Deanna Y. Sverdlov, Nezam H. Afdhal, John V. Frangioni, Deflef Schuppan 46 Cystic Fibrosis Related Diabetes (CFRD) in CF Patients With Cirrhosis Kara Sullivan, A. Moran, B. Holm, S.J. Schwarzenberg 47 Design of a Pilot Study to Identify Optimum Markers of Liver Fibrosis in Children With Cystic Fibrosis Liver Disease (CFLD) Alexandra Vasilescu, Shruti Paranjape, Wikrom Karnsakul, Kathleen B. Schwarz 48 Participants List 51 Notes 65 vi Cystic Fibrosis Liver Disease | Clinical Research Workshop Agenda Monday, June 8, 2009 LISTER HILL AUDITORIUM NIH CAMPUS, BETHESDA, MD DAY ONE 8:00 a.m. – 8:30 a.m. Registration 8:30 a.m. – 8:40 a.m. Welcoming Remarks Jay Hoofnagle SESSION I. CLINICAL ASPECTS AND PREVALENCE OF CF LIVER DISEASE 8:40 a.m. – 9:00 a.m. Cystic Fibrosis Liver Disease: Clinical Features and Definitions Michael Narkewicz 9:00 a.m. – 9:20 a.m. Prevalence and Epidemiology of Cystic Fibrosis Liver Disease Jean Molleston 9:20 a.m. – 9:40 a.m. Cystic Fibrosis Liver Disease: Clinical Outcomes Peter Durie 9:40 a.m. – 10:10 a.m. Discussion 10:10 a.m. – 10:40 a.m. Break SESSION II. PATHOGENESIS OF CF LIVER DISEASE 10:40 a.m. – 11:00 a.m. Pathogenesis of CF Liver Disease Stephen Freedman 11:00 a.m. – 11:20 a.m. The Pathology of Cystic Fibrosis Liver Disease* David Kleiner 11:20 a.m. – 11:40 a.m. Genetic Modifiers of Cystic Fibrosis Liver Disease Michael Knowles * Results of a premeeting working group of clinicians and pathologists who will review pathology of CF liver disease and propose diagnostic criteria and staging and grading systems. Cystic Fibrosis Liver Disease | Clinical Research Workshop ix Agenda Agenda Monday, June 8, 2009 Tuesday, June 9, 2009 LISTER HILL AUDITORIUM CONTINUED NIH CAMPUS, BETHESDA, MD DAY TWO 11:40 a.m. – 12:00 p.m. Protein Folding Defects in Liver Disease: 8:00 a.m. – 8:10 a.m. Introduction to Day 2: Alpha-1-antitrypsin Deficiency Early Assessment and Identification Jeffrey Teckman Edward Doo 12:00 p.m. – 12:30 p.m. Discussion SESSION IV. NONINVASIVE ASSESSMENTS OF CF LIVER DISEASE 12:30 p.m. – 2:00 p.m. Lunch BIOMARKERS SESSION III. MODELS OF CF LIVER DISEASE AND THERAPEUTICS 8:10 a.m. – 8:30 a.m. Biomarkers as Tools for Early Disease Detection Nicole Hamblett 2:00 p.m. – 2:20 p.m. Cystic Fibrosis Liver Disease: CFTR and the Liver Andrew Feranchak 8:30 a.m. – 8:50 a.m. Emerging Techniques for Developing Novel Serum Biomarkers 2:20 p.m. – 2:40 p.m. The CFTR-/- Pig: Liver and Gallbladder Disease Keyur Patel David Meyerholz 8:50 a.m. – 9:10 a.m. Biomarkers of Cystic Fibrosis Liver Disease 2:40 p.m. – 3:00 p.m. Nodular Regenerative Hyperplasia: Ross Shepherd Clinical Features and Course Theo Heller 9:10 a.m. – 9:40 a.m. Discussion 3:00 p.m. – 3:20 p.m. Medical and Surgical Therapy of CF-associated 9:40 a.m. – 10:00 a.m. Break Liver Disease Saul Karpen IMAGING 3:20 p.m. – 3:40 p.m. Liver Transplantation in Children With Cystic Fibrosis: Status and Unanswered Questions 10:00 a.m. – 10:20 a.m. Ultrasound and CT Imaging of Liver Fibrosis and George Mazariegos Other Disease Marilyn Siegel 3:40 p.m. – 4:10 p.m. Discussion 10:20 a.m. – 10:40 a.m. MRI Methods of Assessing Liver 4:10 p.m. – 4:20 p.m. Break Fibrosis and Disease Claude Sirlin 4:20 p.m. – 5:30 p.m. Poster Session x Cystic Fibrosis Liver Disease | Clinical Research Workshop Cystic Fibrosis Liver Disease | Clinical Research Workshop xi Agenda Tuesday, June 9, 2009 CONTINUED IMAGING 10:40 a.m. – 11:00 a.m. Elastography to Assess Liver Fibrosis and Cirrhosis Detlef Schuppan 11:00 a.m. – 11:30 a.m. Discussion 11:30 a.m. – 12:30 p.m. Research Needs for the Future Michael Narkewicz Michael Knowles Patricia Robuck Catherine McKeon Speaker Abstracts Jay H. Hoofnagle Bruce Marshall Marilyn Siegel Edward Doo 12:30 p.m. Adjournment xii Cystic Fibrosis Liver Disease | Clinical Research Workshop Speaker Abstracts Cystic Fibrosis Liver Disease: Clinical Features and Definitions Michael R. Narkewicz, M.D. identified by 15 years of age, affecting up to 7 percent Hewit-Andrews Chair in Pediatric Liver Disease, Professor of patients. Risk factors for cirrhosis have included male of Pediatrics, University of Colorado Denver, School of sex, Hispanic ethnicity, and pancreatic insufficiency. Medicine, The Children’s Hospital, Aurora, CO There has not been any identified genotype/phenotype correlation with CFTR. The pathology is that of multi lobular cirrhosis, often with focal variation. Cystic Fibrosis (CF) is an autosomal recessive disorder that is the most common genetic disorder of Caucasian Other hepatic manifestations include: individuals, with a prevalence of 1 in 2,000 individuals of European descent. It is estimated to affect 30,000 Neonatal Cholestasis: This has been suggested to individuals in the United States. The disease is due to a occur in 1-2 percent of infants with CF. It is more defect in the cystic fibrosis transmembrane conductance common in infants with meconium ileus. In general, the regulator (CFTR). Although the lungs and pancreas cholestasis resolves. The subsequent risk for the develop are the pathopneumonic target organs in CF, many ment of cirrhosis is probably increased, but this remains other organs are affected. These include the small and unclear. large intestine, vas deferens, sinuses, and liver. In 2007, liver disease was the third leading cause of death in CF, Elevated AST, ALT, or GGT: Studies on subjects accounting for 2.3 percent of deaths. identified by newborn screening have shown that the prevalence of abnormal AST, ALT, or GGT is quite CFTR is expressed on the apical membrane of biliary frequent. By 20 years of age, 93 percent of patients have epithelium and not on the hepatocyte. The putative role had at least one abnormal ALT, with 50 percent hav of CFTR is to facilitate water and solute movement via ing at least one ALT greater than 1.5 times the upper chloride secretion and therefore promote bile flow. limit of normal (ULN) and 32 percent having an ALT greater than 2 times the ULN. Persistently abnormal Clinical Features of Liver Disease in CF: The ALT or AST is also quite frequent, with 42 percent of primary end result of liver disease in CF with the patients having a persistently abnormal ALT greater than most significant impact is the development of fibrosis 1.5 times the ULN by 20 years of age.